PanGen Biotech Inc.

KOSDAQ:A222110 Stock Report

Market Cap: ₩70.9b

PanGen Biotech Past Earnings Performance

Past criteria checks 0/6

PanGen Biotech has been growing earnings at an average annual rate of 25.3%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 16.9% per year.

Key information

25.3%

Earnings growth rate

28.2%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate16.9%
Return on equity-3.3%
Net Margin-4.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is PanGen Biotech (KOSDAQ:222110) A Risky Investment?

Aug 13
Is PanGen Biotech (KOSDAQ:222110) A Risky Investment?

Is PanGen Biotech (KOSDAQ:222110) Using Debt In A Risky Way?

Feb 17
Is PanGen Biotech (KOSDAQ:222110) Using Debt In A Risky Way?

PanGen Biotech's (KOSDAQ:222110) Stock Price Has Reduced 33% In The Past Three Years

Dec 26
PanGen Biotech's (KOSDAQ:222110) Stock Price Has Reduced 33% In The Past Three Years

Revenue & Expenses Breakdown

How PanGen Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A222110 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2413,724-5991,8713,296
30 Jun 2411,132-2,7841,8793,188
31 Mar 2410,057-3,1291,8213,200
31 Dec 237,315-4,4891,6843,332
30 Sep 234,909-2,8261,5232,010
30 Jun 234,863-2,8231,4062,545
31 Mar 234,541-4,8861,2943,837
31 Dec 226,501-4,4941,2723,850
30 Sep 226,944-4,8611,1694,137
30 Jun 228,503-4,2791,1513,766
31 Mar 229,781-2,1151,0602,570
31 Dec 217,936-3,3109702,734
30 Sep 217,500-3,4639342,485
30 Jun 215,354-4,5749092,735
31 Mar 215,677-5,2291,0513,049
31 Dec 206,191-4,3561,1083,676
30 Sep 206,016-6,8711,1075,208
30 Jun 205,583-7,0941,1605,331
31 Mar 203,815-8,5031,0765,127
31 Dec 192,881-8,9381,0434,523
30 Sep 193,674-8,7399793,902
30 Jun 194,411-7,1658433,286
31 Mar 195,657-4,8857983,002
31 Dec 185,679-4,6307172,580
30 Sep 184,188-5,8856841,545
30 Jun 183,472-6,3966771,678
31 Mar 182,463-7,3646431,614
31 Dec 172,373-7,0166011,649
30 Sep 172,700-3,3385862,172
30 Jun 172,130-4,6165692,887
31 Mar 171,405-4,6085583,923
31 Dec 161,461-5,1256714,216
30 Sep 162,295-4,5267433,792
30 Jun 162,680-2,8717903,062
31 Mar 163,858-2,8857762,072
31 Dec 153,731-2,6386641,838
30 Sep 154,087-1,2536171,723
30 Jun 154,294-2,5455691,604
31 Mar 153,296-2,5955861,489
31 Dec 143,400-2,1206191,295
31 Dec 133,212-1,312390565

Quality Earnings: A222110 is currently unprofitable.

Growing Profit Margin: A222110 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A222110 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.3% per year.

Accelerating Growth: Unable to compare A222110's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A222110 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A222110 has a negative Return on Equity (-3.32%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:31
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PanGen Biotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae KimDAOL Investment & Securities Co., Ltd.
Bora ChungKorea Investment & Securities Co., Ltd.